• Intestinal TM6SF2 Deficiency Drives MASH via the Gut–Liver A

  2026-06-19

  The referenced Nature Metabolism study elucidates how intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis (MASH) by preserving gut barrier integrity and regulating lipid signaling. This research identifies lysophosphatidic acid (LPA) as a mechanistic link between gut dysbiosis and hepatic inflammation, offering new intervention points for metabolic liver disease.

• Catalpol (N1352): Protocols and Practical Handling for Disea

  2026-06-18

  Catalpol is a multi-pathway iridoid glycoside commonly used in preclinical neuroprotection research, osteoporosis animal models, ischemic stroke models, and liver fibrosis research. This article details practical, product-based protocols, solubility, and workflow considerations for Catalpol (APExBIO N1352), with boundaries on unsupported applications and clear troubleshooting guidance.

• X-ray Triggered Nanomicelle Drug Release for Targeted Chemor

  2026-06-18

  Yao et al. introduce a nanomicelle system that releases caged doxorubicin in response to X-ray induced Cherenkov light, enabling spatially controlled chemoradiation activation. This method achieves nuclear delivery, potent tumor cell killing, and minimizes off-target toxicity, representing a significant advance for localized cancer therapy.

• GSTA1 Drives Glutathione Depletion in α-Amanitin Hepatotoxic

  2026-06-17

  The reference study uncovers a paradoxical mechanism in which hepatic GSTA1, traditionally considered protective, exacerbates α-amanitin-induced liver injury by accelerating glutathione depletion and oxidative stress. These findings reposition GSTA1 as a potential therapeutic target or biomarker for acute hepatotoxicity and highlight new directions for redox-focused intervention.

• Caffeic Acid Phenethyl Ester (CAPE): Applied Workflows in Ne

  2026-06-17

  Caffeic Acid Phenethyl Ester (CAPE) is a robust NF-κB pathway inhibitor, uniquely suited for dissecting inflammatory and angiogenic processes in neurodegeneration and oncology models. This article details optimized CAPE protocols, advanced troubleshooting, and lessons from recent zebrafish neurodegeneration research.

• Dihydrotestosterone (DHT) in Experimental Androgen Signaling

  2026-06-16

  Dihydrotestosterone (DHT) is a versatile tool for dissecting androgen receptor signaling and resistance mechanisms in cancer and neurodegenerative disease models. This guide outlines reproducible workflows, critical troubleshooting strategies, and the latest innovations—bridging molecular insights to robust experimental outcomes.

• Technical Use of Angiotensin I/II (1-5) in Cardiovascular Re

  2026-06-16

  Angiotensin I/II (1-5) is a defined Asp-Arg-Val-Tyr-Ile peptide fragment essential for modeling blood pressure regulation and aldosterone release in renin-angiotensin system workflows. It is best applied in cardiovascular and renal research but should not be used for unrelated peptide signaling studies or off-target applications due to its specific solubility and mechanistic properties.

• Fluorescein Tyramide: Next-Level Signal Amplification in IHC

  2026-06-15

  Fluorescein Tyramide empowers researchers to detect even the faintest targets in immunohistochemistry and in situ hybridization, thanks to its ultra-sensitive signal amplification capabilities. This guide delivers protocol enhancements, troubleshooting tactics, and workflow insights—translating the latest neuroscience findings into practical assay optimization.

• LY-411575: Potent Gamma-Secretase Inhibitor for Research

  2026-06-15

  LY-411575 is a highly potent and selective gamma-secretase inhibitor with sub-nanomolar IC50 values, widely applied in Alzheimer's disease and cancer research. Its precise inhibition of amyloid beta and Notch signaling enables reproducible mechanistic studies in vitro and in vivo. APExBIO’s LY-411575 is a key tool for dissecting disease pathways and validating experimental models.

• KPT-330 (Selinexor): Protocols and Innovations for Cancer Re

  2026-06-14

  KPT-330 (Selinexor) enables precise inhibition of nuclear export, driving apoptosis and tumor growth suppression in challenging cancer models. This guide translates recent breakthroughs and practical workflows into actionable strategies for oncology researchers leveraging APExBIO's trusted supply.

• Viral Induction of RIPK3 Degradation Modulates Necroptosis

  2026-06-13

  Liu et al. (2021) identified a viral strategy wherein orthopoxviruses induce proteasomal degradation of the necroptosis adaptor RIPK3, thereby suppressing necroptosis and modulating inflammation. This mechanism clarifies how viruses exploit the host ubiquitin-proteasome system to evade immune responses, with implications for disease modeling and antiviral research.

• Phosbind Acrylamide: Streamlining Protein Phosphorylation An

  2026-06-12

  Phos binding reagent (Phosbind) acrylamide from APExBIO enables precise, antibody-free detection of protein phosphorylation states via SDS-PAGE. This reagent empowers researchers to dissect kinase signaling with high resolution and facilitates troubleshooting in phosphorylation-dependent workflows.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-06-12

  The referenced study demonstrates that naturally occurring angiotensin peptides, including truncated forms such as Angiotensin 1/2 (5-7), significantly enhance SARS-CoV-2 spike protein binding to AXL, a lesser-known viral entry receptor. These findings reveal a mechanistic link between the renin-angiotensin system and viral pathogenesis, with implications for both hypertension and COVID-19 research.

• Rotavirus-Induced Downregulation of Nrf2 and Redox Defense P

  2026-06-11

  This study reveals how progressive rotavirus infection leads to the suppression of the redox-sensitive transcription factor Nrf2 and its downstream antioxidant genes, clarifying the dynamic regulation of host redox balance during viral infection. The findings have important implications for designing mechanistic studies on oxidative stress, viral pathogenesis, and host defense adaptation.

• SCH772984: Redefining Selective ERK1/2 Inhibition in Tumor P

  2026-06-11

  Explore how SCH772984, a potent ERK1/2 inhibitor, revolutionizes MAPK/ERK pathway inhibition in advanced tumor models. This article offers unique, in-depth analysis linking mechanistic insights to practical assay design.

15555 records 1/1037 page Next 12345 下5页 Last page